Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Forge Resources Intercepts 105 G/T Au in the Payoff Zone at Alotta Project, Yukon (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Ownership  |  Insiders

Stock Quote Today & Recent News Palvella Therapeutics Inc PVLA

Healthcare Biotechnology
Palvella Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies to treat patients suffering from serious, rare genetic skin diseases for which there are no FDA-approved therapies. The Company is developing a pipeline of product candidates based on its patented QTORIN platform, with an initial focus on serious, rare genetic skin... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NDAQ:PVLA)

Palvella Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

GlobeNewswire 7 days ago

Palvella Therapeutics to Present at the Stifel 2025 Healthcare Conference

GlobeNewswire 12 days ago

Palvella Therapeutics Announces New QTORIN(TM) Product Candidate, QTORIN(TM) Pitavastatin, for the Treatment of Disseminated Superficial Actinic Porokeratosis (DSAP), a Rare, Chronic, and Pre-Cancerous Genetic Skin Disease with No FDA-Approved Therapies

GlobeNewswire 13 days ago

Palvella Therapeutics to Host Third Quarter 2025 Financial Results and Corporate Update Conference Call on November 11, 2025

GlobeNewswire November 4, 2025

U.S. Food and Drug Administration Awards Year Two Proceeds from Orphan Products Grant Supporting Palvella Therapeutics' Phase 3 SELVA Trial of QTORIN(TM) Rapamycin for Microcystic Lymphatic Malformations

GlobeNewswire October 13, 2025

Palvella Therapeutics Announces Expansion of QTORIN(TM) Rapamycin's Development into Clinically Significant Angiokeratomas, a Rare, Chronically Debilitating Lymphatic Disease with No FDA-approved Therapies

GlobeNewswire September 24, 2025

Palvella Therapeutics Announces Scientific Publication in Lymphatic Research and Biology Highlighting Recent Advances in the Pathogenesis of Venous Malformations and the Real-World Use of Rapamycin as an Emerging Targeted Therapy

GlobeNewswire September 17, 2025

Palvella Therapeutics Completes Enrollment in Phase 2 TOIVA Trial of QTORIN(TM) Rapamycin for Cutaneous Venous Malformations

GlobeNewswire September 15, 2025

Palvella Therapeutics Strengthens Leadership with Appointment of Accomplished Scientist and Biopharmaceutical Executive David W. Osborne, Ph.D. as Chief Innovation Officer

GlobeNewswire September 3, 2025
View More News ››

Opinion & Analysis (NDAQ:PVLA)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:PVLA)

Be the first to post on this bullboard.

Visionstate Corp.

Visionstate Corp.

Visionstate Corp.is a growth-oriented company that invests in the research and development of the Internet of Things, big ...
View More »